CA-BINARLY
22.6.2022 18:12:10 CEST | Business Wire | Press release
Binarly Inc., a cybersecurity company building technology to address repeatable security failures in the firmware supply chain, today announced $3.6 million in seed funding from WestWave Capital and Acrobator Ventures. Prominent cybersecurity leaders Michael Sutton, Thomas 'Halvar Flake' Dullien, Jamie Butler, Ryan Permeh, Bryson Bort, Pedram Amini, Chris Ueland and David Mandel from Emerging Ventures also joined as investors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622005392/en/
Binarly is co-founded by security pioneers Alex Matrosov and Claudiu Teodorescu , who previously worked on hardware and software security at NVIDIA, Intel Corp., ESET, BlackBerry, Cylance and FireEye. Matrosov, a highly regarded researcher who is regularly credited with major vulnerability discoveries, is co-author of Rootkits and Bootkits , a seminal book that explains how to understand and counter sophisticated, advanced threats buried deep in a machine’s boot process or UEFI firmware.
Binarly has built a SaaS platform for analyzing, understanding and responding to silent, currently undetectable security threats at the firmware layer. Using a combination of machine learning and deep code inspection at the binary level, Binarly enables security teams to have real visibility into hardware and firmware failures and a simple way to recover from sophisticated attacks below the operating system.
Binarly also developed its own technology for vulnerability management and protecting the firmware supply chain from repeatable failures. The company’s approach uses semantic properties of the binary code to improve detection accuracy by limiting the number of false positives.
So far this year, Binarly has coordinated the disclosure of 107 critical firmware security vulnerabilities affecting the entire enterprise device ecosystem . The company worked with security response teams at Insyde, AMI, Lenovo, Dell, HP, HPE, Siemens, Fujitsu, Atos, Intel, AMD and many other vendors to mitigate high-impact security issues across the computing landscape. Many of these vulnerabilities demonstrate the complexities of the firmware supply chain that negatively disrupt the timeline for patch delivery and identification of impacted parties.
“The current approach in the industry is to detect risks related to the firmware by leveraging the current version number of the firmware update against a public database of vulnerabilities and threats. This leads to firmware supply chain failures because known vulnerabilities that are not associated with a certain version number of a firmware release will not be detected thus keeping the 'doors' open for an attacker,” Matrosov said.
“Assessing the impact of a known firmware based vulnerability in a customer environment, at scale, is a problem without a viable solution. We have developed the FwHunt technology that adds semantic context around a known vulnerability to ensure detection while reducing false positives,” Teodorescu said.
Binarly plans to use the investment to speed up research and development initiatives, expand its world-class engineering team, and scale enterprise and device manufacturer adoption of its technologies.
Quotes from investors:
“We are excited to invest in founders Alex and Claudiu at Binarly. We have immense respect for their deep technical expertise and understanding of the firmware security market. We recognize that there are significant exposure issues in addressing firmware security vulnerabilities and we have strong conviction that Binarly will mitigate those concerns - both immediate and in the long term.” - Warren “Bunny” Weiss, Managing Partner, WestWave Capital.
“CISOs from critical infrastructure companies, hyperscalers, and cybersecurity experts rate firmware security as a top-three priority. In a world where IoT, edge devices and the mere size of firmware on devices significantly increases, it’s a matter of ‘when’ not ‘if’ new dominant security solutions are adopted. Why Binarly? They’ve got the best-in-class team discovering vulnerabilities no one else has found and managed to surround themselves with incredible experts.” - Mike Reiner, General Partner, Acrobator Ventures.
“It’s no secret that firmware security presents a growing challenge that needs to be solved. For far too long, hardware manufacturers have relied on security through obscurity and we’re now paying the price as attackers identify and exploit flaws that impact thousands of devices across the globe. Blindly trusting hardware manufacturers is a recipe for disaster. The Binarly team has the expertise and vision to finally execute on delivering a scalable solution to get this problem under control.” - Michael Sutton, Managing Partner, Stonemill Ventures.
About WestWave Capital:
WestWave Capital is an early-stage Venture Capital firm that invests in Seed and Series A Enterprise companies building deep technology solutions. The company’s investments focus on SaaS, Security, Cloud Infrastructure, Blockchain, Analytics, and IoT companies.
About Acrobator Ventures:
Acrobator Ventures is an operator-led venture capital fund focused on early stage tech in the Benelux & CIS operating out of Kiev and Amsterdam.
About Binarly:
Founded in 2021, Binarly brings decades of research experience identifying hardware and firmware security weaknesses and threats. Based in Los Angeles, California, Binarly’s agentless, enterprise-class AI-powered firmware security platform helps protect from advanced threats below the operating system. The company’s technology solves firmware supply chain security problems by identifying vulnerabilities, malicious firmware modifications and providing firmware SBOM visibility without access to the source code. Binarly’s cloud-agnostic solutions give enterprise security teams actionable insights, and reduce the cost and time to respond to security incidents.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220622005392/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
